Hexagen CV (benzalkonium chloride) / Turn Therap - LARVOL DELTA

Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus Aureus Exposure in a Murine Dermatitis Model. (PubMed, Life (Basel)) - "Pretreatment with extended-release polyhexanide (GX-03) reduced disease severity and was associated with decreased expression of IL-36α, IL-36γ, IL-31, and IL-4 following epicutaneous Staphylococcus aureus exposure, while IL-13 expression remained unchanged. These findings suggest that modulation of the cutaneous microenvironment is associated with selective alterations in inflammatory cytokine expression following microbial challenge. Additional studies incorporating microbiologic, histologic, and mechanistic endpoints are needed to further define the biological mechanisms responsible for these observations."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) (clinicaltrials.gov) - P2/3 | N=190 | Recruiting | Sponsor: Turn Therapeutics | Phase classification: P2 ➔ P2/3 | N=110 ➔ 190 | Trial completion date: Jul 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2026 ➔ Jan 2027

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression. (PubMed, J Dermatolog Treat) - "Treatment with GX03 resulted in a significant reduction in disease severity, with mean global assessment scores decreasing from 3.00 in untreated controls to 1.44 in treated animals (52% reduction; p = 0.0003). These findings suggest that extended-release topical polyhexanide (GX03) reduces disease severity in a murine dermatitis model characterized by IL-36 expression."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

GX-03 in AD: A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis) (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Turn Therapeutics

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. (clinicaltrials.gov) - P2b; N=85; Completed; Sponsor: Turn Therapeutics

New P2b trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and Prevention of COVID-19 (Businesswire) - "Turn Therapeutics...announced enrollment of the first subjects in its COVID-19 treatment and prevention clinical trial.... Hexagen, will be administered intranasally...The company expects enrollment to be swift, with multiple patients and healthcare providers enrolled just today. An initial data readout is expected in early March 2021....This randomized, placebo-controlled trial will enroll approximately 100 mild to moderate COVID-19 patients and 50 healthcare workers across four leading hospitals in Panama."

Clinical data • Enrollment status • Infectious Disease • Novel Coronavirus Disease